Document is current

Article History

Received: 11 March 2024

Accepted: 18 March 2024

First Online: 11 May 2024

Conflict of interest

: Dr. Isabel Calvo received speaker honoraria from Gilead, Roche, and MSD and financial support for educational activities from Roche and Daiichi-Sankyo. Dr. M González-Rodríguez received speaker honoraria from Gilead and financial support for educational activities from Roche and Gilead. Dr. F. Neria declares no conflict of interest. Dr. I. Gallegos received consultancy honoraria from Roche, Bristol, and MSD; advisory board honoraria from Roche, Pfizer, Novartis, Daiichi-Astra, Janssen, Sanofi, Eisai, and Lilly and support for educational activities from Roche, Pfizer, and Astellas. Dr. L. García-Sánchez declares no conflict of interest. Dr. R. Sánchez-Gómez declares no conflict of interest. Dr. S. Pérez received speaker honoraria from GE Healthcare, BD, Motiva and financial support for educational activities from GE Healthcare, BD, and Motiva. Dr MF Arenas declares no conflict of interest. Dr L.G. Estévez received consultant/Advisor/speaker honoraria from AstraZeneca, Daiichi Sankyo, Gilead Sciences, MSD, Lilly, and Roche; and from research (paid to Institution) by Roche.

: The study received the approval of the hospital MD Anderson Cancer Center. All procedures performed in the study were in accordance with the ethical standards of the Trust and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: This study is exempt from informed consent as it is a retrospective data collection from the patient's medical records. The data included are part of the usual clinical history of these patients, and data are coded, so they do not suppose any risk to the integrity of the patients.